Xencor Inc posted a presentation on their website with additional clinical data from a Phase 2 study of vudalimab in patients with metastatic castration resistant prostate cancer.
AI Assistant
XENCOR INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.